Thermo Fisher Scientific Webinar Prepares ICP Users for New United States Pharmacopeia Chapters Proposal
CAMBRIDGE, UK (July 15, 2010) - Thermo Fisher Scientific Inc., the world leader in serving science, today announced an informative webinar to help users of inductively coupled plasma (ICP) technologies prepare for the introduction of the proposed United States Pharmacopeia (USP) chapters 232 and 233 on trace elemental impurities in pharmaceutical products. The educational presentation provides the pharmaceutical industry with valuable information about how ICP techniques can facilitate compliance with these emerging legislative requirements. The webinar, entitled "Preparing for the Proposed United States Pharmacopeia Chapters on Trace Elemental Impurities in Pharmaceuticals with ICP Techniques," is now available to view on-demand at http://www.spectroscopynow.com/webinars.
Presented by Matthew Cassap, senior ICP applications specialist for Thermo Fisher Scientific, the comprehensive webinar discusses the limitations of the current USP method governing the analysis of heavy metals in pharmaceutical products. In addition, the webinar provides a historical background and detailed overview of the proposed new chapters.
The presentation features the Thermo Scientific iCAP 6000 Series ICP spectrometer, demonstrating the efficiency of ICP techniques for the reproducible analysis of trace elemental impurities in pharmaceuticals in compliance with the upcoming regulatory requirements. In addition, Thermo Scientific iTEVA Security Software plays a crucial role in legislative compliance efforts as it allows for optimization of instrument parameters and elimination of interferences, delivering maximum accuracy and reliability of results. The webinar will also discuss other elemental analysis techniques and how these can be utilized for the analysis of trace elemental impurities in pharmaceuticals.
Matthew Cassap comments: "The latest Thermo Scientific webinar is essential for pharmaceutical scientists who need to stay up-to-date with elemental analysis techniques and, in particular, ICP-OES and ICP-MS methodologies in order to meet future legislative requirements in pharmaceutical analysis. The proposed USP chapters mark a new era for the analysis of trace elemental impurities in pharmaceutical products and the industry must get ready for the change. The Thermo Scientific range of ICP-OES and ICP-MS instrumentation enables users to comply with the regulatory additions while delivering accurate and repeatable results."
For more information about Thermo Scientific trace elemental analyzers for the pharmaceutical industry, please call +1 800-532-4752, email analyze@thermofisher.com or visit www.thermoscientific.com/trace.
Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
For further press information please contact: Celine Callender, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: thermo@scottpr.com
